Back
NM_000314.8:c.-638C>T
p.? · PTEN
0%
complete
Final classification
VUS
PM2
PTEN
c.-638C>T
p.?
unknown · exon 1

PTEN is a tumor suppressor gene that encodes a phosphatase converting the lipid messenger PIP3 back to PIP2 at the cell membrane, thereby restraining the AKT/mTOR signaling pathway that drives cell growth, proliferation, and survival. It is one of the most frequently mutated genes across many types of human cancer, and its loss promotes unchecked cell growth, survival, and genomic instability, partly through impaired DNA repair. Germline loss-of-function variants in PTEN cause Cowden syndrome, an inherited cancer predisposition disorder associated with elevated risk of breast and thyroid cancer.

This variant

This 5′-UTR PTEN variant occurs in a tumor-suppressor gene whose loss can dysregulate AKT/mTOR signaling and cause Cowden syndrome with increased breast and thyroid cancer risk.

Transcript
NM_000314.8
HGVS · transcript:coding
NM_000314.8:c.-638C>T
GRCh38
chr10:87863832 C>T
GRCh37
chr10:89623589 C>T
VUS: PM2 (supporting) is the only met criterion, and no PTEN Expert Panel Version 3.2 combination rule is satisfied.
Classification rationale
PM2 VUS
PTEN c.-638C>T unknown · exon 1

PM2 supporting: the variant's gnomAD v4.1 allele frequency is below the PTEN VCEP rarity threshold.

PM2 → VUS
LYFE Sciences is an AI system, and it can make mistakes. Criteria may be applied incorrectly, sources may be misread, and a confident-looking classification can still be wrong. Double-check every criterion and its underlying evidence before relying on any call.
Gene diagram · NM_000314.8 · variants mapped to exon structure
PTEN NM_000314.8
Fetching transcript structure from UCSC…
Applied criteria · 1 applied · 10 assessed
MetEvidence satisfies this criterion.
Not metEvaluated against available evidence; threshold not reached.
Not assessedApplies in principle, but no evidence was found to evaluate it.
N/ADoesn't apply to this variant type.
Applied · 1
Strength Supporting Moderate Strong Very strong
PM2 supporting Pathogenic
Met at Supporting: gnomAD v4.1 total AF 2.6136547780222995e-06 is below the PTEN PM2 threshold <0.00001.
The PTEN VCEP Version 3.2 specifies PM2 Supporting for allele frequency <0.00001, with a <0.00002 subpopulation requirement when multiple alleles are present.gnomAD v2.1 reports the variant as absent.gnomAD v4.1 reports total AF 2.6136547780222995e-06 from 1/382606 alleles, with 0 homozygotes.
Assessed · not applied · 3 not met · 7 not assessed
Pathogenic
PS2 Not assessed: no proband phenotype, parental testing, or documented de novo observation is available.
PS4 Not assessed: no proband specificity score or case-control result is available to compare with the PTEN PS4 thresholds (score ≥1 or odds ratio >2 with required statistical support).
PM6 Not assessed: no presumed or proven de novo observation, affected proband, or parental testing is documented.
PP1 Not assessed: no affected relatives, segregation results, or meioses are documented against the 3-meiosis minimum.
Benign
BA1 Not met: gnomAD v4.1 total AF is 2.6136547780222995e-06 versus the PTEN BA1 filtering-AF threshold >0.00056.
BS1 Not met: gnomAD v4.1 total AF is 2.6136547780222995e-06, below the PTEN BS1 Supporting lower threshold 0.0000043.
BS2 Not met: gnomAD v4.1 and gnomAD v3.1 non-cancer each report 0 homozygotes for the variant.
BS4 Not assessed: no affected family members or family-level non-segregation evidence is documented.
BP2 Not assessed: no affected-proband, phase, or cis/trans observation links NM_000314.8:c.-638C>T to another pathogenic or likely pathogenic PTEN variant.
BP5 Not assessed: no two qualifying cases with a highly penetrant alternate diagnosis and non-overlapping PTEN history are documented for this variant.
N/A · 17 PVS1 · PS1 · PS3 · PM1 · PM3 · PM4 · PM5 · PP2 · PP3 · PP4 · PP5 · BS3 · BP1 · BP3 · BP4 · BP6 · BP7
Research & evidence
Population frequency
gnomAD v4.1 screenshot
gnomAD v4.1
gnomAD v2.1 screenshot
gnomAD v2.1
v4.1
This variant is present in gnomAD v4.1 (AF= 2.61365e-06; MAF= 0.00026%, 1/382606 alleles, homozygotes = 0) and has highest observed frequency in the Admixed American population (AF= 4.54835e-05; MAF= 0.00455%, 1/21986 alleles, homozygotes = 0).
v2.1
Absent from gnomAD v2.1.
🇨🇦 CA
Absent from gnomAD-Canada v1.0.
Allele frequency by ancestry
three datasets · side by side
gnomAD v4.1
0.00026% · 1 / 382,606
0 hom
Admixed American
1 / 21,986
0.0045%
+ 9 not observed (Remaining individuals, European (Finnish), Amish, East Asian, Middle Eastern, South Asian, Ashkenazi Jewish, African/African American, European (non-Finnish))
gnomAD v2.1
Absent · 0 / ?
0 hom
Not observed in any ancestry group.
gnomAD Canada 🇨🇦
Absent · 0 / ?
0 hom
Not observed in any ancestry group.
ClinVar screenshot
ClinVar
This variant is absent from ClinVar.
SpliceAI screenshot
In silico
SpliceAI returned NO scores for this variant, so no SpliceAI-based splice prediction is available. This is missing data, NOT evidence of absent splice impact: it must not be used to support BP4 or to argue against PP3/PVS1. Pangolin scores may be present but are not calibrated for PP3/BP4 here.
Functional No data
No calibrated functional assay or RNA evidence was identified for this variant.
OncoKB ↗
COSMIC screenshot
COSMIC
Somatic evidence
COSMIC
This variant has not previously been reported in somatic cancers (COSMIC).
Hotspots
This variant does not lie in a statistically significant cancer hotspot.
COSMIC ↗
Sources & reference links
8Sources
CSpec VCEP
ClinVar
gnomAD v2.1
gnomAD v4.1
gnomAD-Canada
SpliceAI
OncoKB
COSMIC